FDA Grants Kymriah Advanced Treatment for Sefolioma Regenerative Medicine (RMAT)

Novartis today announced that the U.SFood and Drug Administration (FDA) has awarded Kymriah ® advanced regenerative medicine (RMAT) for treatment of recurrent lysopatomer (r/r) follicle-based lymphoma (FL)Kymriah ® is an FDA-approved CAR-T cell therapyRelapse is likely to be Kymriah's third indication"This finding will support the development of Kymriah, which could potentially improve the survival of some patients with follicular lymphoma," said John Tsai, director and chief medical officer of Global Drug Development at Novartisoffollicular lymphoma (FL) is the second most common form of non-Hodgkin's lymphoma (NHL), an inert lymphoma that accounts for about 22 percent of NHL casesAlthough new treatments can improve overall survival, FL is considered an incurable malignancyIn patients with recurrent FL throughout their life cycle, they may receive 5-12 line of previous treatment, and in most cases, relapsed FL patients tend to exhaust treatment options